Clinical Evidence Library
Clinical evidence from guidelines, trials, biomedi…
ClinicalTrials.gov results: useful evidence or reporting trap?. Synthesize what the results database adds to journal publications, then assess major interpretation risks including self reporting, missing fields, inconsistent entries, imprecise outcome definitions, incomplete participant result reporting, and incomplete registry coverage. Include a compact table separating what reviewers can extract, what they should verify, and what should be treated cautiously.
ClinicalTrials.gov as evidence for semaglutide vs tirzepatide weight loss ClinicalTrials.gov is best treated as a **complement** to journal publications, not a replacement. For semaglutide and tirzepatide weight-loss comparisons, it can add protocol-level details and posted summary results, but it d...
ViewPCOS guidelines: what changed from 2018 to 2023?. Walk readers through the shift from 2018 to 2023 as refinement rather than reversal. Emphasize streamlined diagnosis, AMH as an adult-only ultrasound alternative, broader cardiometabolic and psychological risk recognition, and the continued low-to-moderate evidence base.
Did the 2023 PCOS guideline change everything? Not really. It builds on 2018 with the same evidence-based core, just a cleaner diagnostic pathway and broader recognition of what PCOS affects[[cite:1]]. The biggest diagnostic shift is refinement: adults still use the established framework, but 2023 s...
ViewWhen do systematic reviews miss harms?. Narrate why adverse events may be underdetected when reviews rely on randomized trials alone. Explain the need to combine trial data with post-marketing surveillance, spontaneous reports, epidemiology, and unpublished evidence while pre-specifying harms and follow-up.
When systematic reviews of semaglutide or tirzepatide rely on randomized trials alone, they can miss important harms. The trials may include too few people to detect rare adverse events, and they may end before delayed harms appear. Published trial reports can also leave out a lot of adverse event i...
ViewHow well do you know the GLP-1 weight-loss evidence?. Design a short educational quiz around comparative efficacy, heterogeneity of treatment effects, gastrointestinal tolerability, absence of head-to-head trials, and limits of long-term evidence. Use answer feedback to reinforce study-design caveats rather than offering clinical advice.
Q1. In the reviewed evidence, which drug generally produced greater average weight loss? - Semaglutide - Tirzepatide - Exenatide - Liraglutide Answer: Tirzepatide[[cite:1]][[cite:2]] Q2. Which study-design issue most strongly limits confidence in the semaglutide versus tirzepatide comparison? - The ...
ViewFive evidence gaps in falls prevention guidelines. Create five cards covering vitamin D, falls education, hip protectors, digital technologies or wearables, and cognitive factors or patient and caregiver involvement. Keep each card evidence-graded and avoid implying that absence or inconsistency equals ineffectiveness.
Vitamin D: mixed and inconsistent guideline recommendations, with several guidelines making no suggestion; this reflects uncertainty, not proven ineffectiveness. Falls education: recommendations were also inconsistent, showing variable guideline endorsement rather than a settled consensus. Hip prote...
ViewIs 80 percent medication adherence an evidence-based threshold?. Create a short professional thread that explains the historical 80 percent threshold, the systematic review finding that thresholds vary by condition and outcome, and the limits caused by heterogeneous measures. End with implications for evidence reviewers who need to pre-specify adherence definitions.
Is 80% medication adherence really a universal cutoff? The review says that number came from an early empirical definition in antihypertensive care, where taking at least 80% was treated as sufficient[[cite:1]]. But the authors do not treat 80% as a proven standard. They say they could not reject or...
View- 1(current)